Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Enright

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Antimicrobial Agents and Chemotherapy|March 22, 2017
Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological MalignancyCatherine J Byrne, Jason A Roberts, Brett McWhinney, et al.
The Journal of Antimicrobial Chemotherapy|December 23, 2017
Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancyCatherine J Byrne, Ted Parton, Brett McWhinney, et al.
British Journal of Haematology|June 25, 2008
Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patientsBelinda Austen, Giancarlo Barone, Anne Reiman, et al.
British Journal of Haematology|June 23, 2021
Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentationsMichelle Lavin, Patrick T Elder, Denis O'Keeffe, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 21, 2021
Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive DisorderLaura McDonald, Roseann O' Doherty, Eileen Ryan, et al.
Leukemia & Lymphoma|September 20, 2017
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLLNiamh Appleby, David O'Brien, Fiona M Quinn, et al.
Clinical Hematology International|October 1, 2021
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in MyelomaTreen Carson Michael Morris, Mary B Drake, Paul J Kettle, et al.
British Journal of Haematology|August 6, 2013
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemiaSu W Maung, Maeve Leahy, Hilary M O'Leary, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic <i>ERCC6L2</i> variantsHemanth Tummala, Arran D Dokal, Amanda Walne, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Antimicrobial Agents and Chemotherapy|March 22, 2017
Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological MalignancyCatherine J Byrne, Jason A Roberts, Brett McWhinney, et al.
The Journal of Antimicrobial Chemotherapy|December 23, 2017
Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancyCatherine J Byrne, Ted Parton, Brett McWhinney, et al.
British Journal of Haematology|June 25, 2008
Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patientsBelinda Austen, Giancarlo Barone, Anne Reiman, et al.
British Journal of Haematology|June 23, 2021
Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentationsMichelle Lavin, Patrick T Elder, Denis O'Keeffe, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 21, 2021
Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive DisorderLaura McDonald, Roseann O' Doherty, Eileen Ryan, et al.
Leukemia & Lymphoma|September 20, 2017
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLLNiamh Appleby, David O'Brien, Fiona M Quinn, et al.
Clinical Hematology International|October 1, 2021
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in MyelomaTreen Carson Michael Morris, Mary B Drake, Paul J Kettle, et al.
British Journal of Haematology|August 6, 2013
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemiaSu W Maung, Maeve Leahy, Hilary M O'Leary, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic <i>ERCC6L2</i> variantsHemanth Tummala, Arran D Dokal, Amanda Walne, et al.
Pageof 2